Ovid Therapeutics (OVID) Return on Sales (2020 - 2026)

Ovid Therapeutics has reported Return on Sales for 7 years, with the latest figure at 0.03% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 75.0% year-over-year to 0.03%; the trailing twelve-month figure through Mar 2026 stood at 0.03% (up 42.0% YoY), and the FY2025 full-year result was 0.02%, up 44.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.03%, down from 0.13% in the prior quarter.
• The five-year high for Return on Sales was 0.5% in Q2 2024, with the low at 10.78% in Q3 2022.
• Historically, Return on Sales has averaged 1.41% across 5 years, with a median of 0.81% in 2024.
• Annual changes were most pronounced in 2022 — Return on Sales slumped 1079 bps — and 2023, when it jumped 975 bps.
• Ovid Therapeutics' Return on Sales stood at 2.49% in 2022, then jumped by 57 bps to 1.08% in 2023, then fell by 13 bps to 1.22% in 2024, then jumped by 111 bps to 0.13% in 2025, then tumbled by 125 bps to 0.03% in 2026.
• The last three Return on Sales figures came in at 0.03% (Q1 2026), 0.13% (Q4 2025), and 0.92% (Q3 2025), per Business Quant data.